Multiparametric MRI enables early detection of progression and reclassification in patients with low-risk prostate cancer on active surveillance and offers the potential to reduce unnecessary biopsies. However, the reliability and reproducibility of MRI-directed surveillance during follow-up is unclear. A recent study highlights the potential and current shortcomings of this approach.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance
European Radiology Open Access 07 February 2023
-
Risk of progression following a negative biopsy in prostate cancer active surveillance
Prostate Cancer and Prostatic Diseases Open Access 25 August 2022
-
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
World Journal of Urology Open Access 27 January 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bokhorst, L. P. et al. A decade of active surveillance in the PRIAS Study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur. Urol. 70, 954–960 (2016).
Lantz, A. et al. Expanding active surveillance inclusion criteria: a novel nomogram including preoperative clinical parameters and magnetic resonance imaging findings. Eur. Urol. Oncol. 357, 1–8 (2020).
Fujihara, A. et al. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer. BJU Int. https://doi.org/10.1111/bju.15272 (2020).
Moore, C. M. et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-a report of a European School of Oncology task force. Eur. Urol. 71, 648–655 (2017).
Giganti, F. et al. Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. Eur. Radiol. https://doi.org/10.1007/s00330-020-07256-z (2020).
Klotz, L. et al. Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur. Urol. 77, 311–317 (2020).
Ploussard, G. et al. Added value of concomitant systematic and fusion targeted biopsies for grade group prediction based on radical prostatectomy final pathology on positive magnetic resonance imaging. J. Urol. 202, 1182–1187 (2019).
Ploussard, G. et al. Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study. World J. Urol. 38, 1735–1740 (2020).
Stavrinides, V. et al. Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study. Eur. Urol. 78, 443–451 (2020).
Chesnut, G. T. et al. Role of changes in magnetic resonance imaging or clinical stage in evaluation of disease progression for men with prostate cancer on active surveillance. Eur. Urol. 77, 501–507 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests
Additional information
Related links
EAU prostate cancer treatment guidelines: https://uroweb.org/guideline/prostate-cancer/?type=summary-of-changes
Rights and permissions
About this article
Cite this article
Ploussard, G., Renard-Penna, R. MRI-guided active surveillance in prostate cancer: not yet ready for practice. Nat Rev Urol 18, 77–78 (2021). https://doi.org/10.1038/s41585-020-00416-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-00416-2
This article is cited by
-
Risk of progression following a negative biopsy in prostate cancer active surveillance
Prostate Cancer and Prostatic Diseases (2023)
-
Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance
European Radiology (2023)
-
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
World Journal of Urology (2022)